Studies. The vaccine offers “strong protection” against monkeypox.

The Federal Council has already decided on the central purchase of monkeypox vaccine.

KEYSTONE/DPA/SVEN HOPPE (archive image)

The only specifically approved monkeypox vaccine to date offers “strong protection” against the disease with the first dose, according to a new study.

The only specifically approved monkeypox vaccine to date offers “strong protection” against the disease with the first dose, according to a new study. Two weeks after the first dose, the vaccine is estimated to be 78 percent effective, Britain’s health authority said on Tuesday.

“We now know that the first dose of the vaccine provides strong protection against monkeypox,” said Jamie Lopez-Bernal, an epidemiologist at the UK Health Agency.

The findings are based on a study of 363 cases of monkeypox in England from July to November. It is the “strongest UK evidence to date” of the vaccine’s effectiveness, according to the authority.

The vaccine is also used in Switzerland

The vaccine is a German-Danish manufacturer Bavarian Nordic, which is also used in Switzerland. The second vaccination is carried out 28 days after the first dose. “A second dose can be expected to provide even greater and longer-lasting protection,” Lopez-Bernal said.

Monkeypox is a much less dangerous relative of smallpox, which was eradicated about 40 years ago. Typical symptoms of the disease include high fever, swollen lymph nodes and pustules similar to chicken pox.

The disease is transmitted through close body-to-skin contact. According to the World Health Organization (WHO), men who have sex with men are particularly affected. If monkeypox is not treated, the symptoms usually go away on their own after two to four weeks.

Until this year, the disease occurred mainly in West and Central Africa, but since May it has spread to other countries. However, numbers in Western Europe and North America, which are particularly affected, have been falling for several months.

sd/shop

Leave a Comment